Targeting PD-1/PD-L1 in lung cancer: current perspectives
María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit,...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-07-01
|
Series: | Lung Cancer : Targets and Therapy |
Online Access: | http://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTT |
id |
doaj-53cb1147aa7d460ab1939a5683d7eba4 |
---|---|
record_format |
Article |
spelling |
doaj-53cb1147aa7d460ab1939a5683d7eba42020-11-24T22:45:20ZengDove Medical PressLung Cancer : Targets and Therapy1179-27282015-07-012015default557022925Targeting PD-1/PD-L1 in lung cancer: current perspectivesGonzález-Cao MKarachaliou NViteri SMorales-Espinosa DTeixidó CSánchez Ruiz JMolina-Vila MÁSantarpia MRosell RMaría González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitorshttp://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTT |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
González-Cao M Karachaliou N Viteri S Morales-Espinosa D Teixidó C Sánchez Ruiz J Molina-Vila MÁ Santarpia M Rosell R |
spellingShingle |
González-Cao M Karachaliou N Viteri S Morales-Espinosa D Teixidó C Sánchez Ruiz J Molina-Vila MÁ Santarpia M Rosell R Targeting PD-1/PD-L1 in lung cancer: current perspectives Lung Cancer : Targets and Therapy |
author_facet |
González-Cao M Karachaliou N Viteri S Morales-Espinosa D Teixidó C Sánchez Ruiz J Molina-Vila MÁ Santarpia M Rosell R |
author_sort |
González-Cao M |
title |
Targeting PD-1/PD-L1 in lung cancer: current perspectives |
title_short |
Targeting PD-1/PD-L1 in lung cancer: current perspectives |
title_full |
Targeting PD-1/PD-L1 in lung cancer: current perspectives |
title_fullStr |
Targeting PD-1/PD-L1 in lung cancer: current perspectives |
title_full_unstemmed |
Targeting PD-1/PD-L1 in lung cancer: current perspectives |
title_sort |
targeting pd-1/pd-l1 in lung cancer: current perspectives |
publisher |
Dove Medical Press |
series |
Lung Cancer : Targets and Therapy |
issn |
1179-2728 |
publishDate |
2015-07-01 |
description |
María González-Cao,1 Niki Karachaliou,1 Santiago Viteri,1 Daniela Morales-Espinosa,1 Cristina Teixidó,2 Jesús Sánchez Ruiz,3 Miquel Ángel Molina-Vila,2 Mariacarmela Santarpia,4 Rafael Rosell1,2,5,61Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; 2Pangaea Biotech SL, Barcelona, Spain; 3Centro Nacional de Investigación Oncología (CNIO), Madrid, Spain; 4Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy; 5Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; 6Fundación Molecular Oncology Research, Barcelona, SpainAbstract: Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I–III trials with anti-PD-1/PD-L1 antibodies in non-small-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.Keywords: immunotherapy, immunoncology, cancer, checkpoint inhibitors |
url |
http://www.dovepress.com/targeting-pd-1pd-l1-in-lung-cancer-current-perspectives-peer-reviewed-article-LCTT |
work_keys_str_mv |
AT gonzaacutelezcaom targetingpd1pdl1inlungcancercurrentperspectives AT karachalioun targetingpd1pdl1inlungcancercurrentperspectives AT viteris targetingpd1pdl1inlungcancercurrentperspectives AT moralesespinosad targetingpd1pdl1inlungcancercurrentperspectives AT teixidoacutec targetingpd1pdl1inlungcancercurrentperspectives AT saacutenchezruizj targetingpd1pdl1inlungcancercurrentperspectives AT molinavilamaacute targetingpd1pdl1inlungcancercurrentperspectives AT santarpiam targetingpd1pdl1inlungcancercurrentperspectives AT rosellr targetingpd1pdl1inlungcancercurrentperspectives |
_version_ |
1725689000810774528 |